<ARTICLE> 5 <LEGEND> THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS CONTAINED IN THE COMPANY'S QUARTERLY REPORT ON FORM 10-Q FOR THE QUARTER ENDED JUNE 30, 1999 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS. </LEGEND> <MULTIPLIER> 1,000,000 <PERIOD-TYPE> 6-MOS <FISCAL-YEAR-END> DEC-31-1999 <PERIOD-START> JAN-01-1999 <PERIOD-END> JUN-30-1999 <CASH> 200 <SECURITIES> 1,169 <RECEIVABLES> 384 <ALLOWANCES> 21 <INVENTORY> 122 <CURRENT-ASSETS> 2,011 <PP&E> 2,168 <DEPRECIATION> 684 <TOTAL-ASSETS> 3,890 <CURRENT-LIABILITIES> 881 <BONDS> 223 <PREFERRED-MANDATORY> 0 <PREFERRED> 0 <COMMON> 0 <OTHER-SE> 2,785 <TOTAL-LIABILITY-AND-EQUITY> 3,890 <SALES> 1,426 <TOTAL-REVENUES> 1,566 <CGS> 191 <TOTAL-COSTS> 191 <OTHER-EXPENSES> 382<F1> <LOSS-PROVISION> 0 <INTEREST-EXPENSE> 6 <INCOME-PRETAX> 728 <INCOME-TAX> 213 <INCOME-CONTINUING> 515 <DISCONTINUED> 0 <EXTRAORDINARY> 0 <CHANGES> 0 <NET-INCOME> 515 <EPS-BASIC> 1.01<F2> <EPS-DILUTED> 0.96 <FN> <F1>Item consists of research and development expenses. <F2>"EPS-Primary" denotes basic EPS. </FN>